MC4R and breast carcinoma: In summary, we found that the FTO rs7185735 and MC4R rs476828 variants did not influence weight loss or improvement of metabolic parameters within the Mediterranean diet intervention in overweight or obese postmenopausal women with breast cancer receiving adjuvant hormone therapy.